SLC7A5 and rheumatoid arthritis: For example, administration of a specific inhibitor (si-THRIL) reduced IL-1β levels by 45% and simultaneously demonstrated decreased clinical activity in the model [64], while genetic targeting of transporters and matrix components (e.g., SLC7A5, KIAA1199) resulted in decreased RA-FLS invasion and metalloproteinase secretion [29,59], and combined interventions involving microRNAs, as exemplified by miR-214 and tocilizumab, indicated the potential for integrating novel approaches into therapeutic regimens [21].